Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

51.98

Mkt cap

3.1B

Volume

401K

High

51.98

P/E Ratio

-38.45

52-wk high

64.98

Low

48.30

Div yield

N/A

52-wk low

37.55

Citigroup analyst Samantha Semenkow has initiated coverage on MoonLake (NASDAQ:MLTX) with a Buy rating and set a price target of $72.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 12:47 pm

MoonLake Immunotherapeutics shares surged following unconfirmed market rumors of a takeover approach, as discussed in a blog post being circulated among traders.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 3:23 pm

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on MoonLake (NASDAQ: MLTX) and maintained a $92 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 2:19 pm

Over the past 3 months, 18 Wall Street analysts have provided ratings for MoonLake (NASDAQ:MLTX), with 7 bullish, 10 somewhat bullish, and 1 indifferent. The average 12-month price target for MLTX is $76.83, with a high of $92.00 and a low of $59.00. This target has increased by 16.99% over the past month. Analyst ratings are important as they provide investors with insights into a stock's potential performance based on financial analysis and insider information.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 1:00 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $75 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 11:55 am

Wedbush analyst Andreas Argyrides has maintained an Outperform rating on MoonLake (NASDAQ:MLTX) and increased the price target from $86 to $92.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 2:13 pm

Guggenheim analyst Yatin Suneja has reaffirmed a Buy rating on MoonLake (NASDAQ:MLTX) and increased the price target from $70 to $77.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 7:04 pm

MoonLake Immunotherapeutics' stock is up following the release of their Q3 earnings per share (EPS) results, which exceeded expectations. The company also announced that its current financial resources, including cash, cash equivalents, and short-term marketable securities, are expected to fully fund its Phase 3 clinical programs.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 4:10 pm

MoonLake (NASDAQ:MLTX) reported Q3 earnings with an EPS of $-0.18, beating estimates by 21.74% but with no change in revenue from the same period last year. The previous quarter's EPS beat was followed by a 2.95% stock price increase the next day.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 2:30 pm

MoonLake, with $496M in cash, cash equivalents, and short-term marketable securities, is well-capitalized to fund its Phase 3 programs for Hidradenitis Suppurativa and Psoriatic Arthritis, including regulatory submissions and additional research.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.